Preferred Label : Anti-PD-1 Antibody/Anti-CTLA-4 Antibody/CD40 Agonist/TLR9 Agonist SV-102;
NCIt synonyms : Multi-target Biologic Agent SV-102;
NCIt definition : A multi-target fixed-dose combination formulation composed of an antibody directed
against the negative immunoregulatory human cell receptor programmed cell death protein
1 (PD-1; PDCD1; CD279), an antibody directed against the human T-cell-expressed receptor
cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4; CD152), an agonist of
the human B-cell surface antigen CD40, and an agonist of the toll-like receptor 9
(TLR9), with potential immunostimulatory and antineoplastic activities. Upon infusion
of anti-PD-1 antibody/anti-CTLA-4 antibody/CD40 agonist/TLR9 agonist SV-102 into the
area of the lysed tumor, the anti-PD-1 antibody targets, binds to and inhibits PD-1
and the anti-CTLA-4 antibody targets, binds to and inhibits CTLA-4. This inhibits
the PD-1- and CTLA-4-mediated downregulation of T-cell activation and proliferation.
This restores immune function and activates a cytotoxic T-lymphocyte (CTL)-mediated
immune response against tumor cells. The TLR9 agonist targets, binds to and activates
intracellular toll-like receptor 9 (TLR9) in monocytes/macrophages, plasmacytoid dendritic
cells (DCs), natural killer (NK) cells and B-cells. This initiates immune signaling
pathways, activates DCs, NK cells and B-cells, and enhances a CTL-mediated tumor immune
response. The CD40 agonist targets and binds to CD40 on a variety of immune cell types,
such as such as DCs, macrophages and B-cells. This induces CD40-dependent signaling
pathways, triggers the proliferation and activation of antigen-presenting cells (APCs)
and activates T-cells. This further enhances the cytotoxic T-lymphocyte (CTL)-mediated
immune response against tumor cells.;
Molecule name : SV 102; SV-102;
Origin ID : C216216;
concept_is_in_subset
- has_target
